Sensitive Biomarker Analysis of Xue-Fu-Zhu-Yu Capsule for Patients with Qi Stagnation and Blood Stasis Pattern: A
Guang Chen1,2, Haoqiang He1,2, Kun Hu1
1Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Evidence-Based Complementary and Alternative Medicine : Ecam
|December 13, 2019
Summary
FZD8 shows promise as a sensitive biomarker for predicting Xue-Fu-Zhu-Yu capsules (XFZYC) effectiveness. Higher FZD8 levels correlated with better treatment outcomes in patients with Qi Stagnation and Blood Stasis.
Area of Science:
- Biomarker discovery in traditional Chinese medicine.
- Genomics and transcriptomics in personalized medicine.
Background:
- Xue-Fu-Zhu-Yu capsules (XFZYC) are used for conditions related to Qi Stagnation and Blood Stasis.
- Identifying biomarkers can optimize treatment efficacy and patient selection.
Purpose of the Study:
- To identify a sensitive biomarker for predicting the effectiveness of XFZYC.
- To explore potential molecular mechanisms underlying XFZYC action.
Main Methods:
- Nested case-control study analyzing mRNA, miRNA, lncRNA, and circRNA.
- Next-generation sequencing and bioinformatics analysis to identify differentially expressed RNAs.
- Real-time PCR validation of potential biomarkers.
Main Results:
- Over 1100 differentially expressed RNAs were identified.
- FZD8 expression was significantly higher in XFZYC responders (p=0.041).
- Higher FZD8 levels correlated with improved clinical questionnaire scores (p=0.010) with an AUC of 0.765.
Conclusions:
- FZD8 is a potential sensitive biomarker for predicting XFZYC effectiveness.
- Further prospective studies are needed to confirm its diagnostic accuracy.
